C9orf125 Activators
C9orf125 activators engage in a variety of cellular signaling mechanisms to enhance the enzyme's functional activity. One activation route involves the elevation of intracellular cAMP levels, which subsequently activates protein kinase A (PKA). PKA is known for phosphorylating an array of target proteins, possibly including C9orf125 itself, thus potentially enhancing its role in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors. Another pathway of activation arises from the modulation of intracellular calcium levels, which can trigger a cascade of calcium-sensitive signaling events. The alteration in calcium dynamics can indirectly facilitate the activation of C9orf125 by affecting the local lipid environment or protein interactions within the cellular membrane, where the enzyme exerts its function in GPI anchor modification.
In addition to these routes, the inhibition of protein phosphatases such as PP1 and PP2A can result in a general increase in the phosphorylation state withinthe cell, which may lead to an enhanced phosphorylation and consequent activation of C9orf125 or its partner proteins involved in GPI anchor biosynthesis. This hyperphosphorylated cellular state can be induced by specific inhibitors that prevent the dephosphorylation of proteins, thereby indirectly increasing the activity of C9orf125. Moreover, the enzyme's activity can be influenced by alterations in sphingolipid metabolism and signaling, where bioactive lipids serve as ligands for receptors that can modulate membrane-associated signaling cascades. These changes in membrane dynamics and protein interactions may lead to an upregulation of C9orf125's role in the synthesis of GPI anchors. Furthermore, stress-activated protein kinases such as JNK and p38 may also contribute to the activation of C9orf125 through their influence on phosphorylation events, which could modify the activity of proteins within the GPI anchor biosynthesis pathway or directly activate C9orf125.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activator of protein kinase C (PKC) which phosphorylates serine and threonine residues on many proteins. PKC-mediated phosphorylation could enhance the activity of C9orf125 in GPI anchor biosynthesis. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Calcium ionophore that increases intracellular calcium levels, potentially affecting calcium-sensitive signaling pathways and enzymes that could indirectly increase the activity of C9orf125 by modifying the local lipid environment or protein interactions in the membrane. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
cAMP analog that activates cAMP-dependent pathways, including PKA, which may phosphorylate C9orf125 or its substrates, thereby enhancing its function in GPI anchor modification. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels within the cell. This may result in enhanced phosphorylation and activation of C9orf125 or its associated partners in GPI anchor biosynthesis. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Protein phosphatase inhibitor, particularly PP1 and PP2A, potentially increasing the phosphorylation state and activation of C9orf125 or its substrate proteins in the GPI anchor pathway. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Polyphenol found in green tea that inhibits various protein kinases and has been shown to affect multiple signaling pathways, potentially leading to activation of C9orf125 through altered signaling dynamics and phosphorylation patterns. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Activator of stress-activated protein kinases such as JNK and p38, which could lead to phosphorylation and activation of C9orf125 or modify the activity of interacting proteins within the GPI anchor biosynthesis pathway. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
Sphingosine-1-phosphate receptor modulator that influences sphingolipid metabolism and signaling, potentially impacting membrane dynamics and protein interactions, thereby indirectly activating C9orf125 involved in GPI anchor processing. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
PKC inhibitor that can disrupt PKC-mediated signaling, potentially leading to compensatory signaling mechanisms that activate C9orf125 through alternative phosphorylation pathways or protein-protein interactions. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
cAMP analog that can activate PKA and other cAMP-dependent proteins, possibly resulting in phosphorylation and activation of C9orf125 or its associated factors in GPI-anchor modification. | ||||||